KEYNOTE-394

NCT03062358 📎

Regimen

Experimental
pembrolizumab 200 mg Q3W + BSC
Control
placebo + BSC

Population

Asian patients with advanced hepatocellular carcinoma, progression or intolerance to sorafenib or oxaliplatin-based chemotherapy

Key finding

mOS 14.6 vs 13.0 mo (HR 0.79, 95% CI 0.63-0.99, p=0.0180) — **MET prespecified threshold** (p<0.0193); mPFS 2.6 vs 2.3 mo (HR 0.74, p=0.0032); ORR 12.7% vs 1.3%; **Asia-only cohort** (HBV ~77%), contrast with negative KN-240 global ITT

Source: PMID 36455168

Timeline

    Guideline citations

    • NCCN HCC (p.71)